Dishman Carbogen Amcis Ltd Stock Price Today (NSE: DCAL)
Fundamental Score
Dishman Carbogen Amcis Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Dishman Carbogen Amcis Ltd share price today is ₹195.76, up +0.00% on NSE/BSE as of 17 February 2026. Dishman Carbogen Amcis Ltd (DCAL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹3.73K (Cr). The 52-week high for DCAL share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 24.96x, DCAL is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of -0.32% and a debt-to-equity ratio of 0.40.
Dishman Carbogen Amcis Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Dishman Carbogen Amcis Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Dishman Carbogen Amcis Share Price: A Financial Analysis
The pharmaceutical sector is currently experiencing a dynamic shift towards specialized contract development and manufacturing (CDMO), driven by large pharma companies outsourcing complex molecule development and manufacturing to increase efficiency. This analysis focuses on the Dishman Carbogen Amcis share price, currently at ₹200.88999938964844, and its underlying financial health relative to industry trends.
At a price-to-earnings (PE) ratio of 24.96, Dishman Carbogen Amcis appears to be trading near the average of its sector peers. However, its Return on Capital Employed (ROCE) of 2.42% raises concerns. ROCE measures how effectively a company generates profits from its capital employed. A low ROCE suggests the company is not efficiently utilizing its capital to generate returns, potentially hindering long-term value creation and its ability to fund future growth initiatives. This significantly weakens the company's moat compared to peers like
Mankind Pharma Ltd, known for its strong management quality and efficient operations reflected in significantly higher ROCE ratios. Efficient management directly impacts capital allocation and project execution, leading to better returns.Comparing Dishman Carbogen Amcis to other sector players like Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd requires a deeper dive into their respective business models and growth trajectories. While the PE ratio provides a snapshot of valuation, a sustainable competitive advantage, often gauged by ROCE and other factors, is crucial for long-term success. A ROCE of 2.42% does not indicate a strong, resilient business compared to other players in the market.
A low ROCE erodes the company's ability to reinvest in innovation, attract and retain talent, and expand its market share. This is especially important in the highly competitive pharmaceutical industry. Further due diligence is needed to assess the reasons behind the low ROCE and the company's plans to improve it.
Disclaimer: This financial analysis of Dishman Carbogen Amcis share price is based on publicly available information and is part of an 80-parameter fundamental audit verified by Sweta Mishra. This analysis is for informational purposes only and should not be construed as investment advice. It is an observational assessment of the company's financial standing and should not be interpreted as a recommendation to buy or sell the stock.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Dishman Carbogen Amcis Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of DCAL across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Attractive Valuation (P/E: 24.96 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (88.81%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Balanced Promoter Holding (59.32%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (-0.32%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (2.42%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Revenue Contraction (-17.29%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Weak Interest Coverage (1.77x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-69.39 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 9.44%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Dishman Carbogen Amcis Ltd Financial Statements
Comprehensive financial data for Dishman Carbogen Amcis Ltd including income statement, balance sheet and cash flow
About DCAL (Dishman Carbogen Amcis Ltd)
Dishman Carbogen Amcis Ltd (DCAL) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹3.73K (Cr). Dishman Carbogen Amcis Ltd has delivered a Return on Equity (ROE) of -0.32% and a ROCE of 2.42%. The debt-to-equity ratio stands at 0.40, reflecting the company's capital structure. Investors tracking DCAL share price can monitor key metrics including P/E ratio, promoter holding of 59.32%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
DCAL Share Price: Frequently Asked Questions
What is the current share price of Dishman Carbogen Amcis Ltd (DCAL)?
As of 17 Feb 2026, 10:09 am IST, Dishman Carbogen Amcis Ltd share price is ₹195.76. The DCAL stock has a market capitalisation of ₹3.73K (Cr) on NSE/BSE.
Is DCAL share price Overvalued or Undervalued?
DCAL share price is currently trading at a P/E ratio of 24.96x, compared to the industry average of 31.77x. Based on this relative valuation, the Dishman Carbogen Amcis Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of DCAL share price?
The 52-week high of DCAL share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Dishman Carbogen Amcis Ltd share price?
Key factors influencing DCAL share price include quarterly earnings growth (Sales Growth: -17.29%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Dishman Carbogen Amcis Ltd a good stock for long-term investment?
Dishman Carbogen Amcis Ltd shows a 5-year Profit Growth of N/A% and an ROE of -0.32%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.40 before investing in DCAL shares.
How does Dishman Carbogen Amcis Ltd compare with its industry peers?
Dishman Carbogen Amcis Ltd competes with major peers in the Pharmaceuticals. Investors should compare DCAL share price P/E of 24.96x and ROE of -0.32% against the industry averages to determine competitive standing.
What is the P/E ratio of DCAL and what does it mean?
DCAL share price has a P/E ratio of 24.96x compared to the industry average of 31.77x. Investors pay ₹25 for every ₹1 of annual earnings.
How is DCAL performing according to Bull Run's analysis?
DCAL has a Bull Run fundamental score of 30.4/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does DCAL belong to?
DCAL operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Dishman Carbogen Amcis Ltd share price.
What is Return on Equity (ROE) and why is it important for DCAL?
DCAL has an ROE of -0.32%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Dishman Carbogen Amcis Ltd generates profits from shareholders capital.
How is DCAL debt-to-equity ratio and what does it indicate?
DCAL has a debt-to-equity ratio of 0.40, which indicates moderate leverage that should be monitored.
What is DCAL dividend yield and is it a good dividend stock?
DCAL offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Dishman Carbogen Amcis Ltd shares.
How has DCAL share price grown over the past 5 years?
DCAL has achieved 5-year growth rates of: Sales Growth 5.82%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in DCAL and why does it matter?
Promoters hold 59.32% of DCAL shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Dishman Carbogen Amcis Ltd.
What is DCAL market capitalisation category?
DCAL has a market capitalisation of ₹3732 crores, placing it in the Small-cap category.
How volatile is DCAL stock?
DCAL has a beta of N/A. A beta > 1 suggests the Dishman Carbogen Amcis Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is DCAL operating profit margin trend?
DCAL has a 5-year average Operating Profit Margin (OPM) of 14.36%, indicating the company's operational efficiency.
How is DCAL quarterly performance?
Recent quarterly performance shows Dishman Carbogen Amcis Ltd YoY Sales Growth of -17.29% and YoY Profit Growth of 88.81%.
What is the institutional holding pattern in DCAL?
DCAL has FII holding of 8.07% and DII holding of 1.37%. Significant institutional holding often suggests professional confidence in the Dishman Carbogen Amcis Ltd stock.